Thymidylate synthase expression in rectal cancer and proliferation, assessed by cyclin a and Ki-67 expression

Anticancer Research

Volumn 22, Issue 5, 2002, Pages 3113-3116

  Edler, David ^a   Hallstrom, Marja ^a   Ragnhammar, Peter ^a   Blomgren, Henric ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cyclin A; Immunohistochemistry; Ki 67; Proliferation; Rectal cancer; Thymidylate synthase

Indexed keywords

ANTIBODY; CYCLIN A; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY KI 67; MONOCLONAL ANTIBODY TS106; NCL CYCLIN A ANTIBODY; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECTUM CANCER; TUMOR GROWTH;

CELL DIVISION; CYCLINS; FORMALDEHYDE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; PARAFFIN EMBEDDING; RECTAL NEOPLASMS; THYMIDYLATE SYNTHASE; TISSUE FIXATION;

EID: 0036765416     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Romain S, Spyratos F, Descotes F, Daver A, Rostaing-Puissant B, Bougnoux P, Colonna M, Bolla M and Martin PM: Prognostic of DNA-synthesizing enzyme activities (thymidine kinase and thymidylate synthase) in 908 T1-T2, N0-N1, M0 breast cancers: a retrospective multicenter study. Int J Cancer 87: 860-868, 2000.
2. Pestalozzi BC, Peterson HF, Gelber RD, Goldhirsch A, Gusterson BA, Trihia H, Lindtner J, Cortes-Funes H, Simmoncini E, Byrne MJ, Golouh R, Rudenstam CM, Castiglione-Gertsch M, Allegra CJ and Johnston PG: Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol 15: 1923-1931, 1997.
3. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV and Leichman L: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407-1412, 1995.
4. Suda Y, Kuwashima Y, Tanaka Y, Uchida K and Akazawa S: Immunohistochemical detection of thymidylate synthase in advanced gastric cancer: a prognostic indicator in patients undergoing gastrectomy followed by adjuvant' chemotherapy with 5-fluoropyrimidines. Anticancer Res 19: 805-810, 1999.
5. Kuniyasu T, Nakamura T, Tabuchi Y and Kuroda Y: Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody: the clinical role of thymidylate synthase as a prognostic indicator and its therapeutic usefulness. Cancer 83: 1300-1306, 1998.
6. Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Konda B and Leichman L: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16: 309-316, 1998.
7. Suzuki M, Tsukagoshi S, Saga Y, Ohwada M and Sato I: Enhanced expression of thymidylate synthase may be of prognostic importance in advanced cervical cancer. Oncology 57: 50-54, 1999.
8. Suzuki M, Ohwada M, Tamada T and Tsuru S: Thymidylate synthase activity as a prognostic factor in ovarian cancer. Oncology 51: 334-338, 1994.
9. Edler D, Hallstrom M, Johnston PG, Magnusson I, Ragnhammar P, and Blomgren H: Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. Clin Cancer Res 6: 1378-1384, 2000.
10. Edler D, Kressner U, Ragnhammar P, Johnston PG, Magnusson I, Glimelius B, Pahlman L, Lindmark G and Blomgren H: Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival. Clin Cancer Res 6: 488-492, 2000.
11. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA and Allegra CJ: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12: 2640-2647, 1994.
12. van Triest B, Pinedo HM, Blaauwgeers JLM, van Diest PJ, Schoenmakers PS, Voorn DA, Smid K, Hoekman K, Hoitsma HFW, and Peters JG: Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res 6: 1063-1072, 2000.
13. Lenz HJ, Danenberg KD, Leichman CG, Florentine B, Johnston PG, Groshen S, Zhou L, Xiong YP, Danenberg PV and Leichman LP: p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. Clin Cancer Res 4: 1227-1234, 1998.
14. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M and Danenberg PV: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15: 3223-3229, 1997.
15. Paradiso A, Simone G, Petroni S, Leone B, Vallejo C, Lacava J, Romero A, Machiavelli M, De Lena M, Allegra CJ and Johnston PG: Thymidylate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 82: 560-567, 2000.
16. Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C, Lionetto R, Maley F and Sobrero A: Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 17: 1760-1770, 1999.
17. Cascinu S, Aschele C, Barni S, Debernardis D, Baldo C, Tunesi G, Catalano V, Staccioli MP, Brenna A, Muretto P and Catalano G: Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin Cancer Res 5: 1996-1999, 1999.
18. Davies MM, Johnston PG, Kaur S and Allen-Mersh TG: Colorectal liver metastasis thymidylate synthase staining correlates with response to hepatic arterial floxuridine. Clin Cancer Res 5: 325-328, 1999.
19. Takenoue T, Nagawa H, Matsuda K, Fujii S, Nita ME, Hatano K, Kitayama J, Tsuruo T and Muto T: Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. Ann Surg Oncol 7: 193-198, 2000.
20. Yamachika T, Nakanishi H, Inada K, Tsukamoto T, Kato T, Fukushima M, Inoue M and Tatematsu M: A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 82: 70-77, 1998.
21. Edler D, Glimelius B, Hallstrom M, Jakobsen A, Johnston P, Magnusson I, Ragnhammar P and Blomgren H: Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 20, 7: 1721-1728, 2002.
22. Cascinu S, Graziano F, Valentini M, Catalano V, Giordani P, Staccioli MP, Rossi C, Baldelli AM, Grianti C, Muretto P and Catalano G: Vascular endothelial growth factor expression, S-phase fraction and thymidylate syntase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy. Annals Oncol 12: 239-244, 2001.
23. Allegra CJ, Parr AL, Wold LE, Mahoney MR, Sargent DJ, Johnston P, Klein P, Behan K, O'Connell MJ, Levitt R, Kugler JW, Tirona MT and Goldberg RM: Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 20, 7: 1735-1743, 2002.
24. Navalgund LG, Rossana C, Muench AJ and Johnson LF: Cell cycle regulation of thymidylate synthetase gene expression in cultured mouse fibroblasts. J Biol Chem 255: 7386-7390, 1980.
25. Pestalozzi BC, McGinn CJ, Kinsella TJ, Drake JC, Glennon MC, Allegra CJ and Johnston PG: Increased thymidylate synthase protein levels are principally associated with proliferation but not cell cycle phase in asynchronous human cancer cells. Br J Cancer 71: 1151-1157, 1995.
26. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U and Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715, 1984.
27. Dutta A, Chandra R, Leiter LM and Lester S: Cyclins as markers of tumor proliferation: immunocytochemical studies in breast cancer. Proc Natl Acad Sci USA 92: 5386-5390, 1995.
28. Bodey B, Williams RT, Carbonaro-Hall DA, Horvath A, Tolo VT, Luck JVJr, Taylor CR and Hall FL: Immunocytochemical detection of cyclin A and cyclin D in formalin-fixed, paraffin-embedded tissues: novel, pertinent markers of cell proliferation. Mod Pathol 7: 846-852, 1994.
29. Edler D, Blomgren H, Allegra CJ, Johnston PG, Lagerstedt U, Magnusson I and Ragnhammar P: Immunohistochemical determination of thymidylate synthase in colorectal cancer - methodological studies. Eur J Cancer 33: 2278-2281, 1997.
30. Hsu SM, Raine L and Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29: 577-580, 1981.
31. van Triest B, Pinedo HM, Blaauwgeers JL, van Diest PJ, Schoenmakers PS, Voorn DA, Smid K, Hoekman K, Hoitsma HF and Peters GJ: Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res 6: 1063-1072, 2000.
32. Matsumura K, Tsuji T, Shinozaki F, Sasaki K and Takahashi M: Immunohistochemical determination of growth fraction in human tumors. Pathol Res Pract 184: 609-613, 1989.
33. Kubota Y, Petras RE, Easley KA, Bauer TW, Tubbs RR and Fazio VW: Ki-67-determined growth fraction versus standard staging and grading parameters in colorectal carcinoma. A multivariate analysis. Cancer 70: 2602-2609, 1992.
34. Jansson A and Sun XF: Ki-67 expression in relation to clinicopathological variables and prognosis in colorectal adenocarcinomas. Apmis 105: 730-734, 1997.
35. Chen YT, Henk MJ, Carney Kj, Wong WD, Rothenberger DA, Zheng T, Feygin M and Madoff RD: Prognostic significance of tumor markers in colorectal cancer patients: DNA index, S-phase fraction, p53 expression, and Ki-67 index. J Gastrointest Surg 1: 266-273, 1997.
36. Lanza GJr, Cavazzini L, Borghi L, Ferretti S, Buccoliero F and Rubbini M: Immunohistochemical assessment of growth fractions in colorectal adenocarcinomas with monoclonal antibody Ki-67. Relation to clinical and pathological variables. Pathol Res Pract 186: 608-618, 1990.
37. Handa K, Yamakawa M, Takeda H, Kimura S and Takahashi T: Expression of cell cycle markers in colorectal carcinoma: superiority of cyclin A as an indicator of poor prognosis. Int J Cancer 84: 225-233, 1999.
38. Wang A., Yoshimi N, Suzui M, Yamauchi A, Tarao M and Mori H: Different expression patterns of cyclins A, D1 and E in human colorectal cancer. J Cancer Res Clin Oncol 122: 122-126, 1996.
39. Chu E, Copur SM, Ju J, Chen TM, Khleif S, Voeller DM, Mizunuma N, Patel M, Maley GF, Maley F and Allegra CJ: Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex. Mol Cell Biol 19: 1582-1594, 1999.
40. Ju J, Pedersen-Lane J, Maley F and Chu E: Regulation of p53 expression by thymidylate synthase. Proc Natl Acad Sci USA 96: 3769-3774, 1999.
41. Schmitz JC, Yu D, Agrawal S and Chu E: Effect of 2′-O-methyl antisense ORNs on expression of thymidylate synthase in human colon cancer RKO cells. Nucleic Acids Res 29: 415-422, 2001.
42. Chu E, Takechi T, Jones KL, Voeller DM, Copur SM, Maley GF, Maley F, Segal S and Allegra CJ: Thymidylate synthase binds to cmyc RNA in human colon cancer cells and in vitro. Mol Cell Biol 15: 179-185, 1995.